Shionogi To Submit NDA For Flu Drug Premivir In Japan
This article was originally published in PharmAsia News
Shionogi announced the company is preparing for a NDA submission in Japan for anti-viral flu agent and neuraminidase inhibitor premivir within the year. The Osaka-based company said a domestic clinical trial of the drug has shown promising results and it is conducting a thorough data analysis and preparing application documents for a NDA submission. Shionogi obtained the exclusive rights to premivir in Japan from BioCryst Pharmaceuticals of the U.S, where the drug is under Phase II development. (Click here for more - Japanese language
You may also be interested in...
Wave’s Duchenne muscular dystrophy drug and Lilly’s chronic pain R&D will test the agency’s CID meeting pilot program, while FDA issues draft guidance that highlights potential uses for complex innovative trial designs.
Agency officials can now discuss the ideas that have been accepted, though not in great detail.
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.